Renaissance Technologies’s Ascendis Pharma A/S ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$31.9M Buy
119,699
+2,367
+2% +$553K 0.04% 505
2026
Q1
$26.8M Buy
+117,332
New +$26.3M 0.04% 543
2023
Q3
Sell
-82,699
Closed -$7.38M 3642
2023
Q2
$7.38M Buy
+82,699
New +$7.2M 0.01% 1186
2020
Q3
Sell
-55,082
Closed -$8.15M 3362
2020
Q2
$8.15M Buy
55,082
+4,004
+8% +$550K 0.01% 1348
2020
Q1
$5.75M Buy
51,078
+21,235
+71% +$2.76M 0.01% 1485
2019
Q4
$4.15M Sell
29,843
-44,756
-60% -$4.97M ﹤0.01% 1970
2019
Q3
$7.18M Sell
74,599
-105,200
-59% -$11.7M 0.01% 1603
2019
Q2
$20.7M Buy
179,799
+91,000
+102% +$10.9M 0.02% 944
2019
Q1
$10.5M Buy
+88,799
New +$7.78M 0.01% 1353
2018
Q4
Sell
-41,900
Closed -$2.97M 3366
2018
Q3
$2.97M Sell
41,900
-14,600
-26% -$1M ﹤0.01% 2086
2018
Q2
$3.76M Buy
56,500
+49,860
+751% +$3.28M ﹤0.01% 1955
2018
Q1
$434K Sell
6,640
-8,860
-57% -$498K ﹤0.01% 2961
2017
Q4
$621K Sell
15,500
-18,000
-54% -$654K ﹤0.01% 2833
2017
Q3
$1.21M Buy
33,500
+8,030
+32% +$230K ﹤0.01% 2504
2017
Q2
$707K Buy
+25,470
New +$673K ﹤0.01% 2675

Other funds holding ASND

Renaissance Technologies's ASND Position: Q2 2026 in Review

Renaissance Technologies increased its Ascendis Pharma A/S (ASND) stake by 2% in Q2 2026, buying an estimated $553K and bringing the position to 119,699 shares worth $31.9M. The position accounts for 0.04% of the portfolio, ranked #505.

Renaissance Technologies first reported a position in ASND in Q2 2017 and has held it in 15 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Renaissance Technologies held 119,699 shares of Ascendis Pharma A/S worth $31.9M as of Q2 2026.
  • Renaissance Technologies bought 2,367 Ascendis Pharma A/S shares in Q2 2026, an estimated $553K.
  • Ascendis Pharma A/S made up 0.04% of Renaissance Technologies's portfolio in Q2 2026, its #505 holding.
  • Renaissance Technologies first reported a position in Ascendis Pharma A/S in Q2 2017 and has held it in 15 quarters since.
  • 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.